## M S Patnaik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/956353/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vacuoles, <scp>E1</scp> enzyme, Xâ€linked, autoinflammatory, somatic ( <scp>VEXAS</scp> ) syndrome: a presentation of two cases with dermatologic findings. International Journal of Dermatology, 2023, 62, .	1.0	8
2	Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population. Hepatology Communications, 2022, 6, 399-410.	4.3	84
3	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	1.3	3
4	<i>3q21</i> deletion affects <i>GATA2</i> and is associated with myelodysplastic syndrome. British Journal of Haematology, 2022, 196, 1120-1123.	2.5	0
5	Genetic features and clinical outcomes of patients with isolated and comutated <i>DDX41</i> -mutated myeloid neoplasms. Blood Advances, 2022, 6, 528-532.	5.2	27
6	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood, 2022, 139, 1066-1079.	1.4	24
7	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British Journal of Haematology, 2022, 196, 975-983.	2.5	14
8	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2022, 97, E62.	4.1	17
9	Targeting ineffective hematopoiesis in myelodysplastic syndromes. American Journal of Hematology, 2022, 97, 171-173.	4.1	5
10	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
11	Clonal hematopoiesis: Molecular and clinical implications. Leukemia Research, 2022, 113, 106787.	0.8	15
12	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer Journal, 2022, 12, 12.	6.2	1
13	Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2022, 97, 352-372.	4.1	35
14	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer Journal, 2022, 12, 7.	6.2	5
15	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts ( <scp>MDSâ€RS</scp> ) but not in <scp>MDS</scp> / <scp>MPNâ€RSâ€T</scp> . American Journal of Hematology 2022, 97, .	/, 4.1	6
16	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	6.2	5
17	<i>SF3B1</i> -mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	3.5	3
18	Erythrocytosis associated with <i>EPAS1</i> ( <i>HIF2A</i> ), <i>EGLN1</i> ( <i>PHD2</i> ), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. Haematologica, 2022, 107, 1201-1204.	3.5	4

#	Article	IF	CITATIONS
19	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leukemia Research, 2022, 116, 106818.	0.8	5
20	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
21	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia, 2022, 36, 1693-1696.	7.2	1
22	Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Advances, 2022, 6, 5227-5231.	5.2	5
23	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, .	4.1	10
24	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nature Communications, 2022, 13, 1434.	12.8	17
25	Realâ€world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. American Journal of Hematology, 2022, 97, .	4.1	13
26	How I diagnose and treat chronic myelomonocytic leukemia. Haematologica, 2022, 107, 1503-1517.	3.5	9
27	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3― Blood Cancer Journal, 2022, 12, 55.	6.2	4
28	Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. Leukemia and Lymphoma, 2022, , 1-9.	1.3	2
29	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
30	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. Current Hematologic Malignancy Reports, 2022, 17, 61-68.	2.3	14
31	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A realâ€world experience. British Journal of Haematology, 2022, 198, .	2.5	7
32	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19014-e19014.	1.6	0
33	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
34	A dynamic 3â€ <del>f</del> actor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	4.1	7
35	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	1.6	0
36	Characteristics and prognosis of <i>DDX41</i> and <i>GATA2</i> mutated myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19010-e19010.	1.6	0

#	Article	IF	CITATIONS
37	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, 2022, 140, 1408-1418.	1.4	13
38	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	6.2	7
39	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 2021, 35, 644-649.	7.2	8
40	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood, 2021, 137, 513-523.	1.4	9
41	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80
42	Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 508-510.	2.4	0
43	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11
44	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1180-1189.	2.4	80
45	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962.	2.4	3
46	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 764-767.	1.3	7
47	CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research, 2021, 81, 2666-2678.	0.9	5
48	Myelodysplastic syndromes with ring sideroblasts ( <scp>MDSâ€RS</scp> ) and <scp>MDS</scp> /myeloproliferative neoplasm with <scp>RS</scp> and thrombocytosis ( <scp>MDS/MPNâ€RSâ€T</scp> ) – " <scp>2021</scp> update on diagnosis, riskâ€stratification, and management― American Journal of Hematology, 2021, 96, 379-394.	4.1	29
49	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	2.7	8
50	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12
51	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
52	Novel therapeutic targets for chronic myelomonocytic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101244.	1.7	2
53	Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current Hematologic Malignancy Reports, 2021, 16, 256-266.	2.3	0
54	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus <scp>HMA</scp> ± venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	4.1	7

#	Article	IF	CITATIONS
55	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 328-350.	3.8	2
56	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
57	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	6.2	6
58	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.	6.2	11
59	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	6.2	5
60	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. Kidney International Reports, 2021, 6, 1050-1057.	0.8	1
61	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia, 2021, 35, 3299-3303.	7.2	18
62	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia, 2021, 35, 3329-3333.	7.2	6
63	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	5.2	19
64	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of Clinical Medicine, 2021, 10, 2264.	2.4	5
65	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	4.1	46
66	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	12.8	44
67	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leukemia and Lymphoma, 2021, 62, 2568-2586.	1.3	10
68	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring <i>SF3B1</i> Mutations. American Journal of Clinical Pathology, 2021, 156, 679-690.	0.7	10
69	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 2739-2751.	7.2	10
70	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
71	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest, 2021, 159, 2325-2333.	0.8	11
72	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330.	4.1	6

#	Article	IF	CITATIONS
73	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Journal of Clinical Oncology, 2021, 39, 3328-3339.	1.6	72
74	Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	2.5	2
75	Remarkable stability in clonal hematopoiesis involving leukemiaâ€driver genes in patients without underlying myeloid neoplasms. American Journal of Hematology, 2021, 96, E392-E396.	4.1	3
76	<i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	2.5	9
77	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	4.1	19
78	Isolated T ell acute lymphoblastic leukemic optic disc infiltration. American Journal of Hematology, 2021, 96, 1717-1718.	4.1	0
79	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	6.2	4
80	Outcomes of venetoclaxâ€based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E433-E436.	4.1	10
81	Clinical Heterogeneity of the VEXAS Syndrome. Mayo Clinic Proceedings, 2021, 96, 2653-2659.	3.0	58
82	Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?. Seminars in Hematology, 2021, 58, 226-229.	3.4	22
83	Highâ€oxygenâ€affinity hemoglobinopathyâ€associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. American Journal of Hematology, 2021, 96, 1647-1654.	4.1	8
84	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. Blood Cancer Journal, 2021, 11, 170.	6.2	6
85	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genetics, 2021, 260-261, 1-5.	0.4	0
86	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. Blood, 2021, 138, 1492-1492.	1.4	0
87	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
88	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. Blood, 2021, 138, 36-36.	1.4	0
89	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	1.4	0
90	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2592-2592.	1.4	0

#	Article	IF	CITATIONS
91	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood, 2021, 138, 219-219.	1.4	3
92	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 3684-3684.	1.4	0
93	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 1470-1470.	1.4	0
94	A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal, 2021, 11, 183.	6.2	0
95	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. Blood, 2021, 138, 3657-3657.	1.4	1
96	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). Blood, 2021, 138, 1096-1096.	1.4	0
97	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	1.4	1
98	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. Blood, 2021, 138, 2158-2158.	1.4	5
99	Histopathologic Characterization of Vexas Syndrome. Blood, 2021, 138, 4656-4656.	1.4	0
100	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
101	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i> : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. Blood, 2021, 138, 3693-3693.	1.4	2
102	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3
103	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. Blood, 2021, 138, 2164-2164.	1.4	1
104	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	3.5	105
105	Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. Clinical Research in Cardiology, 2020, 109, 616-627.	3.3	18
106	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 2020, 34, 656-661.	7.2	32
107	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Modern Pathology, 2020, 33, 334-343.	5.5	18
108	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of <i>TET2</i> and <i>ZRSR2</i> mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving <i>CDK2NA/2NB</i> and <i>MTAP</i> . American Journal of Hematology, 2020, 95, E31-E34.	4.1	2

#	Article	IF	CITATIONS
109	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of <i>BCRâ€ABL1</i> like ( <scp>P</scp> hiladelphia chromosome like) <scp>B</scp> â€acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	4.1	4
110	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 97-115.	4.1	105
111	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	7.2	68
112	Myelodysplastic/myeloproliferative neoplasms – Justified inclusion as unique biological entities. Best Practice and Research in Clinical Haematology, 2020, 33, 101135.	1.7	0
113	Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Current Opinion in Hematology, 2020, 27, 2-10.	2.5	7
114	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes – Advances in treatment. Best Practice and Research in Clinical Haematology, 2020, 33, 101130.	1.7	0
115	Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer Journal, 2020, 10, 120.	6.2	2
116	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer Journal, 2020, 10, 121.	6.2	21
117	Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology American Society of Hematology Education Program, 2020, 2020, 460-464.	2.5	22
118	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematology American Society of Hematology Education Program, 2020, 2020, 450-459.	2.5	29
119	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	4.6	56
120	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American Journal of Hematology, 2020, 95, 1511-1521.	4.1	83
121	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	5.2	51
122	MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S339.	0.4	1
123	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Advances, 2020, 4, 5425-5430.	5.2	16
124	Hereditary Predisposition to Hematopoietic Neoplasms. Mayo Clinic Proceedings, 2020, 95, 1482-1498.	3.0	25
125	Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms. Rheumatic Disease Clinics of North America, 2020, 46, 429-444.	1.9	12
126	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	6.2	8

#	Article	IF	CITATIONS
127	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal, 2020, 10, 36.	6.2	14
128	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
129	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	1.3	17
130	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€̃graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1
131	Response to erythropoiesisâ€stimulating agents in patients with WHOâ€defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). British Journal of Haematology, 2020, 189, e104-e108.	2.5	8
132	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood, 2020, 136, 1477-1486.	1.4	43
133	A populationâ€based study of chronic eosinophilic <scp>leukemiaâ€not</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	4.1	6
134	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
135	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. Anticancer Research, 2020, 40, 3883-3888.	1.1	2
136	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. British Journal of Haematology, 2020, 190, e316-e320.	2.5	9
137	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica, 2020, 105, e84-e86.	3.5	12
138	Transplant Characteristics and Outcomes of Philadelphia (Ph)-like Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation, 2020, 26, S114-S115.	2.0	2
139	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GL11-STAT3 transcriptional complex. Journal of Biological Chemistry, 2020, 295, 2698-2712.	3.4	9
140	Treatment of Acquired Sideroblastic Anemias. Hematology/Oncology Clinics of North America, 2020, 34, 401-420.	2.2	3
141	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 2020, 34, 2519-2524.	7.2	25
142	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. American Journal of Clinical Pathology, 2020, 153, 656-663.	0.7	11
143	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	1.8	1
144	Phenotypic correlates and prognostic outcomes of <scp><i>TET2</i></scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	4.1	3

#	Article	IF	CITATIONS
145	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. American Journal of Hematology, 2020, 95, E114-E117.	4.1	14
146	Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome. Best Practice and Research in Clinical Haematology, 2020, 33, 101171.	1.7	13
147	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp> â€2 pandemic. American Journal of Hematology, 2020, 95, E203-E208.	4.1	10
148	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. JAMA Dermatology, 2020, 156, 631.	4.1	9
149	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Blood. 2020. 136. 19-21.	1.4	12
150	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	1.4	10
151	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
152	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
153	Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, 2020, 136, 909-913.	1.4	36
154	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	5.2	9
155	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2020, 136, 31-32.	1.4	0
156	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. Blood, 2020, 136, 10-11.	1.4	0
157	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
158	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
159	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. Blood, 2020, 136, 17-18.	1.4	0
160	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	1.4	0
161	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. Blood, 2020, 136, 43-44.	1.4	0
162	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	1.4	0

#	Article	IF	CITATIONS
163	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	1.4	0
164	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. Blood, 2020, 136, 27-28.	1.4	13
165	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	1.4	0
166	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2019, 54, 204-211.	2.4	41
167	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. Blood Cancer Journal, 2019, 9, 65.	6.2	17
168	Phenotypic heterogeneity associated with germline <i>GATA2</i> haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286.	1.3	4
169	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518.	5.2	62
170	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	3.0	6
171	QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. Leukemia and Lymphoma, 2019, 60, 3512-3520.	1.3	6
172	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings, 2019, 94, 1753-1768.	3.0	21
173	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings, 2019, 94, 1467-1474.	3.0	12
174	Concomitant Erdheim hester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. British Journal of Haematology, 2019, 187, e51-e54.	2.5	13
175	Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis. Journal of Clinical Apheresis, 2019, 34, 666-671.	1.3	7
176	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	4.1	9
177	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leukemia and Lymphoma, 2019, 60, 2483-2487.	1.3	3
178	A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). Frontiers in Immunology, 2019, 10, 777.	4.8	59
179	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
180	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia, 2019, 33, 2466-2480.	7.2	66

#	Article	IF	CITATIONS
181	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	3.0	103
182	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	4.1	51
183	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	6.2	9
184	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1232-1239.	2.0	6
185	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. Advances in Cell and Gene Therapy, 2019, 2, e48.	0.9	11
186	Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 2019, 21, 101.	4.0	10
187	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.8	0
188	Novel germline missense <i>DDX41</i> variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. Leukemia and Lymphoma, 2019, 60, 1337-1339.	1.3	9
189	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology, 2019, 98, 331-337.	1.8	5
190	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 2019, 133, 697-709.	1.4	408
191	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the <i>JAK2</i> V617F mutation. Haematologica, 2019, 104, e236-e239.	3.5	18
192	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Riskâ€stratification, and Management― American Journal of Hematology, 2019, 94, 475-488.	4.1	35
193	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leukemia and Lymphoma, 2019, 60, 821-824.	1.3	2
194	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American Journal of Hematology, 2019, 94, 5-9.	4.1	7
195	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	1.3	9
196	Differential expression of interferonâ€induced genes and other tissueâ€based biomarkers in acute graftâ€versusâ€host disease vs. lupus erythematosus in skin. Clinical and Experimental Dermatology, 2019, 44, e81-e88.	1.3	4
197	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	1.4	1
198	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. Blood, 2019, 134, 3003-3003.	1.4	1

#	Article	IF	CITATIONS
199	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4581-4581.	1.4	3
200	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. Blood, 2019, 134, 4273-4273.	1.4	2
201	A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 4234-4234.	1.4	4
202	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Blood, 2019, 134, 558-558.	1.4	19
203	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). Blood, 2019, 134, 4182-4182.	1.4	1
204	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 4232-4232.	1.4	0
205	Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression. Blood, 2019, 134, 3790-3790.	1.4	2
206	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. Blood, 2019, 134, 3005-3005.	1.4	0
207	Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2987-2987.	1.4	0
208	Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a. Blood, 2019, 134, 4220-4220.	1.4	1
209	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
210	Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. Blood, 2019, 134, 1222-1222.	1.4	0
211	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). Blood, 2019, 134, 5441-5441.	1.4	0
212	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 4500-4500.	1.4	0
213	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. Blood, 2019, 134, 5406-5406.	1.4	0
214	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2981-2981.	1.4	0
215	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	1.4	4
216	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. Blood, 2019, 134, 3863-3863.	1.4	1

#	Article	IF	CITATIONS
217	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. Blood, 2019, 134, 3300-3300.	1.4	0
218	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. Blood, 2019, 134, 2588-2588.	1.4	0
219	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	1.4	0
220	Preâ€enthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. American Journal of Hematology, 2018, 93, E144-E146.	4.1	2
221	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. Leukemia and Lymphoma, 2018, 59, 2737-2739.	1.3	9
222	<i>U2AF1</i> mutation variants in myelodysplastic syndromes and their clinical correlates. American Journal of Hematology, 2018, 93, E146-E148.	4.1	15
223	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. Human Immunology, 2018, 79, 532-536.	2.4	6
224	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	7.2	101
225	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2018, 8, 18.	6.2	19
226	<i>FGFR1</i> rearranged hematological neoplasms – molecularly defined and clinically heterogeneous. Leukemia and Lymphoma, 2018, 59, 1520-1522.	1.3	8
227	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology, 2018, 93, 649-654.	4.1	40
228	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	4.1	50
229	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer Journal, 2018, 8, 12.	6.2	41
230	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838.	2.5	32
231	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. American Journal of Hematology, 2018, 93, E103-E107.	4.1	1
232	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia, 2018, 32, 1850-1856.	7.2	25
233	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biology of Blood and Marrow Transplantation, 2018, 24, 1906-1913.	2.0	21
234	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leukemia and Lymphoma, 2018, 59, 2998-3001.	1.3	13

#	Article	IF	CITATIONS
235	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 32.	6.2	12
236	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. British Journal of Haematology, 2018, 182, 141-145.	2.5	4
237	Subacute demyelinating polyradiculoneuropathy complicating Epstein–Barr virus infection in <i>GATA2</i> haploinsufficiency. Muscle and Nerve, 2018, 57, 150-156.	2.2	6
238	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). American Journal of Hematology, 2018, 93, E27-E30.	4.1	18
239	Therapy relatedâ€chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from <i>de novo</i> CMML. American Journal of Hematology, 2018, 93, 65-73.	4.1	49
240	The importance of <i>FLT3</i> mutational analysis in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2273-2286.	1.3	66
241	In Reply—Short Telomere Syndromes, Biological Aging, and Hematopoietic Stem Cell Transplantation. Mayo Clinic Proceedings, 2018, 93, 1685-1687.	3.0	1
242	Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes. Mayo Clinic Proceedings, 2018, 93, 834-839.	3.0	20
243	45-Year-Old Man With Abdominal Pain and Splenomegaly. Mayo Clinic Proceedings, 2018, 93, e113-e117.	3.0	0
244	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E398-E401.	4.1	1
245	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3â€ITD</i> mutational status. American Journal of Hematology, 2018, 93, E401-E404.	4.1	3
246	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer Journal, 2018, 8, 82.	6.2	24
247	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	4.1	25
248	Practiceâ€relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. American Journal of Hematology, 2018, 93, E383-E386.	4.1	2
249	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Advances, 2018, 2, 370-380.	5.2	90
250	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	5.2	68
251	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. American Journal of Hematology, 2018, 93, 824-840.	4.1	101
252	Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside. Mayo Clinic Proceedings, 2018, 93, 904-916.	3.0	81

#	Article	IF	CITATIONS
253	Genotype–phenotype correlation of hereditary erythrocytosis mutations, a single center experience. American Journal of Hematology, 2018, 93, 1029-1041.	4.1	38
254	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 341-347.	2.3	4
255	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology, 2018, 93, E355-E357.	4.1	2
256	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
257	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leukemia Research, 2018, 71, 60-62.	0.8	18
258	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518.	7.2	26
259	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	6.1	72
260	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategoryâ€specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466.	4.1	24
261	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirtyâ€nine patients. American Journal of Hematology, 2018, 93, 1347-1357.	4.1	10
262	Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia, 2018, 32, 2093-2094.	7.2	2
263	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	3.0	20
264	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	1.4	1
265	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. Blood, 2018, 132, 961-961.	1.4	3
266	Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML. Blood, 2018, 132, 662-662.	1.4	59
267	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9
268	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Blood, 2018, 132, 1773-1773.	1.4	3
269	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821.	1.4	12
270	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. Blood, 2018, 132, 1443-1443.	1.4	0

#	Article	IF	CITATIONS
271	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	1.4	0
272	Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1813-1813.	1.4	1
273	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. Blood, 2018, 132, 2113-2113.	1.4	0
274	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. Blood, 2018, 132, 5440-5440.	1.4	1
275	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. Blood, 2018, 132, 3456-3456.	1.4	0
276	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
277	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
278	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. Blood, 2018, 132, 4287-4287.	1.4	0
279	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. Blood, 2018, 132, 582-582.	1.4	0
280	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	1.4	0
281	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. Blood, 2018, 132, 3050-3050.	1.4	0
282	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. Blood, 2018, 132, 3100-3100.	1.4	0
283	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. Blood, 2018, 132, 2689-2689.	1.4	0
284	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. Blood, 2018, 132, 1771-1771.	1.4	0
285	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Laboratory Investigation, 2017, 97, 494-497.	3.7	24
286	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis ( <scp>RARS</scp> â€ <scp>T</scp> ): 2017 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2017, 92, 297-310.	4.1	61
287	The 2016 revised World Health Organization definition of â€~myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single <i>versus</i> double cytogenetic abnormalities. British Journal of Haematology, 2017, 178, 57-60.	2.5	7
288	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1478-1484.	2.0	31

#	Article	IF	CITATIONS
289	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology, 2017, 92, 866-871.	4.1	17
290	Midostaurin for the treatment of acute myeloid leukemia. Future Oncology, 2017, 13, 1853-1871.	2.4	9
291	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leukemia and Lymphoma, 2017, 58, 2588-2597.	1.3	12
292	Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities. Current Hematologic Malignancy Reports, 2017, 12, 290-299.	2.3	6
293	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer Journal, 2017, 7, e550-e550.	6.2	21
294	Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645.	4.1	40
295	WILD syndrome is GATA2 deficiency: A novel deletion in the GATA2 gene. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1149-1152.e1.	3.8	16
296	<i>FLT3</i> Mutation Testing in Acute Myeloid Leukemia. JAMA Oncology, 2017, 3, 991.	7.1	3
297	Targeted next generation sequencing and identification of risk factors in <scp>W</scp> orld <scp>H</scp> ealth <scp>O</scp> rganization defined atypical chronic myeloid leukemia. American Journal of Hematology, 2017, 92, 542-548.	4.1	64
298	Clinical characteristics and platelet phenotype in a family with <i>RUNX1</i> mutated thrombocytopenia. Leukemia and Lymphoma, 2017, 58, 1963-1967.	1.3	10
299	Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2019-2020.	2.0	0
300	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer Journal, 2017, 7, e592-e592.	6.2	66
301	Immunophenotypic and molecular comparison between allogeneic and autologous graftâ€vsâ€host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. Journal of Cutaneous Pathology, 2017, 44, 1087-1091.	1.3	2
302	Targeted nextâ€generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSSâ€R. American Journal of Hematology, 2017, 92, 1311-1317.	4.1	73
303	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer Journal, 2017, 7, e584-e584.	6.2	68
304	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. American Journal of Hematology, 2017, 92, E626-E627.	4.1	3
305	Nucleophosmin 1 ( <i>NPM1</i> ) mutations in chronic myelomonocytic leukemia and their prognostic relevance. American Journal of Hematology, 2017, 92, E614-E618.	4.1	34
306	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clinic Proceedings, 2017, 92, 1617-1624.	3.0	53

M S Patnaik

#	Article	IF	CITATIONS
307	Clinical outcomes of <scp>HLA</scp> â€ <scp>DPB</scp> 1 mismatches in 10/10 <scp>HLA</scp> â€matched unrelated donorâ€recipient pairs undergoing allogeneic stem cell transplant. European Journal of Haematology, 2017, 99, 275-282.	2.2	11
308	DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61.	4.1	60
309	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1488-1493.	1.3	47
310	von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. British Journal of Haematology, 2017, 176, 994-997.	2.5	4
311	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leukemia and Lymphoma, 2017, 58, 872-881.	1.3	29
312	Acute leukemia in pregnancy: a single institution experience with 23 patients. Leukemia and Lymphoma, 2017, 58, 1052-1060.	1.3	15
313	Influenza infection in neutropenic adults. Infectious Diseases, 2017, 49, 141-146.	2.8	4
314	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
315	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658.	6.2	16
316	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	1.8	55
317	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Case Reports in Hematology, 2017, 2017, 1-4.	0.4	0
318	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget, 2017, 8, 94569-94579.	1.8	4
319	Coagulation abnormalities and haemostatic surgical outcomes in 142 patients with Noonan syndrome. Haemophilia, 2017, 23, e237-e240.	2.1	12
320	The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Cancer Journal (Sudbury,) Tj ETQq0 0 0	rgBT/Over 2.0	rlock 10 Tf 50
321	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the <i>FIP1L1â€PDGFRA</i> mutation. American Journal of Hematology, 2016, 91, E10-1.	4.1	20
322	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARSâ€T) and the role of nextâ€generation sequencing. American Journal of Hematology, 2016, 91, 492-498.	4.1	70
323	Grey platelet syndrome misdiagnosed as <scp>ITP</scp> . British Journal of Haematology, 2016, 173, 662-662.	2.5	5

324Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization. American Journal of<br/>Clinical Pathology, 2016, 146, 86-94.0.722

#	Article	IF	CITATIONS
325	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation. Biology of Blood and Marrow Transplantation, 2016, 22, 1710-1716.	2.0	24
326	Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leukemia Research Reports, 2016, 5, 7-10.	0.4	13
327	Chronic myelomonocytic leukemia: molecularly contaminated, but not defined. Leukemia and Lymphoma, 2016, 57, 1751-1752.	1.3	3
328	Vancomycinâ€resistant <i><scp>E</scp>nterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transplant Infectious Disease, 2016, 18, 913-920.	1.7	40
329	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leukemia Research, 2016, 50, 112-115.	0.8	8
330	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia, 2016, 30, 2273-2275.	7.2	23
331	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2016, 91, 631-642.	4.1	53
332	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. European Journal of Haematology, 2016, 97, 313-320.	2.2	21
333	Myelodysplastic syndromes: Contemporary review and how we treat. American Journal of Hematology, 2016, 91, 76-89.	4.1	153
334	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood, 2016, 127, 1449-1458.	1.4	99
335	A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood, 2016, 128, 1913-1917.	1.4	33
336	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer Journal, 2016, 6, e472-e472.	6.2	42
337	Targeted next generation sequencing of <scp>PDGFRB</scp> rearranged myeloid neoplasms with monocytosis. American Journal of Hematology, 2016, 91, E12-4.	4.1	20
338	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer Journal, 2016, 6, e414-e414.	6.2	23
339	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, 1431-1439.	2.0	26
340	Fanconi Anemia—Protean Manifestations of Defective DNA Repair. Mayo Clinic Proceedings, 2016, 91, 824-825.	3.0	0
341	Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clinical Epigenetics, 2016, 8, 68.	4.1	62
342	Clinical and laboratory characteristics in congenitalANKRD26mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets, 2016, 27, 712-715.	2.3	19

#	Article	IF	CITATIONS
343	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. International Journal of Hematology, 2016, 103, 409-415.	1.6	0
344	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2016, 18, 216-226.	1.7	14
345	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLAâ€matched peripheral blood hematopoietic cell transplantation after reducedâ€intensity conditioning. Transfusion, 2016, 56, 518-527.	1.6	14
346	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1714-1715.	1.3	7
347	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer Journal, 2016, 6, e385-e385.	6.2	96
348	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer Journal, 2016, 6, e393-e393.	6.2	102
349	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings, 2016, 91, 259-272.	3.0	23
350	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer Journal, 2016, 6, e405-e405.	6.2	30
351	47-Year-Old Man With Pruritus. Mayo Clinic Proceedings, 2016, 91, 241-245.	3.0	1
352	The Incidence and Severity of Oral Mucositis among AllogeneicÂHematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 605-616.	2.0	103
353	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biology of Blood and Marrow Transplantation, 2016, 22, 579-583.	2.0	19
354	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Blood, 2016, 128, 100-100.	1.4	18
355	Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2248-2248.	1.4	19
356	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. Blood, 2016, 128, 2798-2798.	1.4	3
357	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. Blood, 2016, 128, 3604-3604.	1.4	3
358	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	1.4	5
359	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. Blood, 2016, 128, 4343-4343.	1.4	1
360	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. Blood, 2016, 128, 4694-4694.	1.4	1

#	Article	IF	CITATIONS
361	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. Blood, 2016, 128, 1987-1987.	1.4	3
362	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. Blood, 2016, 128, 1617-1617.	1.4	0
363	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. Blood, 2016, 128, 5541-5541.	1.4	0
364	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. Blood, 2016, 128, 300-300.	1.4	0
365	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259.	1.4	0
366	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. Blood, 2016, 128, 4653-4653.	1.4	0
367	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 110-110.	1.4	4
368	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986.	1.4	0
369	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. Blood, 2016, 128, 5534-5534.	1.4	1
370	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1988-1988.	1.4	0
371	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 4593-4593.	1.4	0
372	Coagulation Abnormalities and Hemostatic Surgical Outcomes in 142 Patients with Noonan Syndrome. Blood, 2016, 128, 1417-1417.	1.4	0
373	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. Blood, 2016, 128, 5542-5542.	1.4	0
374	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1989-1989.	1.4	0
375	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making: A Qualitative Patient-Oriented Survey Study. Blood, 2016, 128, 3588-3588.	1.4	0
376	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. Blood, 2016, 128, 3599-3599.	1.4	0
377	Spectrum of myeloid neoplasms and immune deficiency associated with germline <i><scp>GATA</scp>2</i> mutations. Cancer Medicine, 2015, 4, 490-499.	2.8	43
378	Temozolomide induced bone marrow Suppression–A single institution outcome analysis and review of the literature. American Journal of Hematology, 2015, 90, E183-4.	4.1	17

#	Article	IF	CITATIONS
379	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. American Journal of Hematology, 2015, 90, 411-416.	4.1	50
380	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AASingle-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 699-704.	0.4	11
381	Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells. Leukemia, 2015, 29, 1605-1608.	7.2	33
382	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e39-e41.	0.4	6
383	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 2015, 5, e270-e270.	6.2	39
384	Angiosarcoma of the Prostate Gland following Brachytherapy for Prostatic Adenocarcinoma. Current Urology, 2015, 8, 109-112.	0.6	6
385	Refractory anemia with ring sideroblasts and <scp>RARS</scp> with thrombocytosis. American Journal of Hematology, 2015, 90, 549-559.	4.1	41
386	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal, 2015, 5, e333-e333.	6.2	117
387	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	3.0	16
388	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer Journal, 2015, 5, e315-e315.	6.2	31
389	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 546-549.	0.4	20
390	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. New England Journal of Medicine, 2015, 373, 908-919.	27.0	276
391	Prognostic impact of combined NPM1+/FLT3â~ genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia Research, 2015, 39, 1207-1213.	0.8	7
392	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. Thrombosis Research, 2015, 135, 109-113.	1.7	36
393	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 1923-1923.	1.4	1
394	Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood, 2015, 126, 2140-2140.	1.4	2
395	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. Blood, 2015, 126, 2563-2563.	1.4	2
396	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Blood, 2015, 126, 3210-3210.	1.4	1

#	Article	IF	CITATIONS
397	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 453-453.	1.4	20
398	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. Blood, 2015, 126, 5234-5234.	1.4	3
399	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. Blood, 2015, 126, 55-55.	1.4	3
400	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. Blood, 2015, 126, 736-736.	1.4	2
401	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	1.4	0
402	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). Blood, 2015, 126, 4067-4067.	1.4	0
403	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. Blood, 2015, 126, 5260-5260.	1.4	0
404	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. Blood, 2015, 126, 4980-4980.	1.4	0
405	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	1.4	0
406	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	1.4	0
407	Iron Deficiency Anemia Associated with Extracorporeal Photophoresis: A Retrospective Analysis. Blood, 2015, 126, 951-951.	1.4	0
408	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	1.4	0
409	Clinico-Pathological Features and Outcomes in Patients with Congenital Sideroblastic Anemias. Blood, 2015, 126, 3355-3355.	1.4	0
410	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 2864-2864.	1.4	0
411	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	1.4	0
412	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. Blood, 2015, 126, 3747-3747.	1.4	0
413	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	1.4	0
414	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. Blood, 2015, 126, 5254-5254.	1.4	0

#	Article	IF	CITATIONS
415	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	1.4	0
416	Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients. Blood, 2015, 126, 1013-1013.	1.4	0
417	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	1.4	2
418	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Research, 2014, 49, 100.	1.3	56
419	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia, 2014, 28, 2206-2212.	7.2	237
420	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp> ayo <scp>C</scp> linicâ€ <scp>F</scp> rench <scp>C</scp> onsortium <scp>S</scp> tudy. American Journal of Hematology, 2014, 89, 1111-1115.	4.1	129
421	<i>MYST3/CREBBP</i> Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer. Case Reports in Oncological Medicine, 2014, 2014, 1-3.	0.3	4
422	Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. British Journal of Haematology, 2014, 165, 273-286.	2.5	86
423	CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia, 2014, 28, 1370-1371.	7.2	11
424	Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. Blood, 2014, 124, 5577-5577.	1.4	18
425	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood Cancer Journal, 2013, 3, e122-e122.	6.2	14
426	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia, 2013, 27, 1504-1510.	7.2	190
427	Myeloid malignancy presenting with a platelet storage pool disorder. Leukemia and Lymphoma, 2013, 54, 1800-1801.	1.3	3
428	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 690-693.	4.1	30
429	Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	6
430	Spliceosome mutations involving <i>SRSF2</i> , <i>SF3B1</i> , and <i>U2AF35</i> in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. American Journal of Hematology, 2013, 88, 201-206.	4.1	134
431	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia, 2013, 27, 2100-2102.	7.2	85
432	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. Blood, 2013, 122, 1510-1510.	1.4	10

#	Article	IF	CITATIONS
433	Real-World "myelodysplastic Syndrome-unclassifiable―and Its Comparison With "refractory Cytopenia With Multi-Lineage dysplasia―and "refractory anemia― Blood, 2013, 122, 1574-1574.	1.4	3
434	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. Blood, 2013, 122, 1732-1732.	1.4	1
435	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2013, 122, 2803-2803.	1.4	2
436	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. Blood, 2013, 122, 2821-2821.	1.4	1
437	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. Blood, 2013, 122, 4049-4049.	1.4	1
438	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662.	1.4	11
439	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 1405-1405.	1.4	0
440	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. Blood, 2013, 122, 2794-2794.	1.4	0
441	Clinical and Molecular Profile Of Hereditary Antithrombin (AT) Deficiency: A Single Institution Cohort. Blood, 2013, 122, 2369-2369.	1.4	8
442	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. Blood, 2013, 122, 5472-5472.	1.4	0
443	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048.	1.4	0
444	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	1.4	0
445	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. Blood, 2013, 122, 2098-2098.	1.4	0
446	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. Blood, 2013, 122, 5226-5226.	1.4	0
447	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 3873-3873.	1.4	1
448	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1334-1334.	1.4	1
449	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. Blood, 2013, 122, 916-916.	1.4	0
450	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375.	1.4	0

#	Article	IF	CITATIONS
451	Incidence Of Symptomatic Venous Thromboembolism In Patients With Hemophilia Undergoing Joint Replacement Surgery: A Retrospective Study. Blood, 2013, 122, 2348-2348.	1.4	0
452	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. Blood, 2013, 122, 2081-2081.	1.4	0
453	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	1.4	0
454	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia, 2012, 26, 101-105.	7.2	129
455	Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts. Blood, 2012, 119, 5674-5677.	1.4	73
456	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 2012, 119, 569-572.	1.4	203
457	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711.	1.4	0
458	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	1.4	0
459	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts Blood, 2012, 120, 2803-2803.	1.4	0
460	Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center Blood, 2012, 120, 2850-2850.	1.4	0
461	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. Blood, 2012, 120, 3790-3790.	1.4	0
462	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1476-1476.	1.4	1
463	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 423-423.	1.4	0
464	Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia, 2011, 25, 266-270.	7.2	78
465	Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. American Journal of Hematology, 2011, 86, 393-398.	4.1	23
466	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	1.4	2
467	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. Blood, 2011, 118, 3803-3803.	1.4	15
468	No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. Blood, 2011, 118, 4259-4259.	1.4	1

#	Article	IF	CITATIONS
469	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971.	1.4	0
470	Age and platelet count are IPSSâ€independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. European Journal of Haematology, 2010, 84, 105-108.	2.2	49
471	Chromosome 9p24 abnormalities: prevalence, description of novel <i>JAK2</i> translocations, <i>JAK2</i> V617F mutation analysis and clinicopathologic correlates. European Journal of Haematology, 2010, 84, 518-524.	2.2	23
472	Chromosome 8p11.2 translocations: Prevalence, FISH analysis for <i>FGFR1</i> and <i>MYST3</i> , and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. American Journal of Hematology, 2010, 85, 238-242.	4.1	39
473	WHO-defined â€~myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 2010, 24, 1283-1289.	7.2	88
474	Clinical & Molecular Analysis of Patients with Type 2 (Qualitative) Hereditary Antithrombin (AT) Deficiency. Blood, 2010, 116, 4201-4201.	1.4	0
475	Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2010, 116, 2705-2705.	1.4	0
476	Molecular diagnosis of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics, 2009, 9, 481-492.	3.1	13
477	The complete evaluation of erythrocytosis: congenital and acquired. Leukemia, 2009, 23, 834-844.	7.2	102
478	Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia, 2009, 23, 1343-1345.	7.2	255
479	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, 2009, 113, 5727-5736.	1.4	484
480	FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia Research, 2006, 30, 965-970.	0.8	131
481	A Man with Progressive Effort Intolerance and Splenomegaly. , 0, , 393-399.		0
482	Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk. Current Hematologic Malignancy Reports, 0, , .	2.3	0